For Healthcare Professionals Only
Rheumatology
Videos
Initiating IL-6 Receptor Inhibitor Therapy
In this interview, Prof. Taylor explains factors to consider when initiating IL-6R inhibitor therapy in patients with rheumatoid arthritis. It is part of the course Fast Facts: Interleukin-6 Receptor Inhibition in Rheumatoid Arthritis, which is free-to-access at this link.
Interleukin-6 in rheumatoid arthritis
Christopher Holroyd explains the use of IL-6R inhibitors in rheumatoid arthritis. This video is part of the course Fast Facts: IL-6 Receptor Inhibition in Rheumatoid Arthritis, which is free-to-access at this link.
Treatments in rheumatoid arthritis
Jérôme Avouac discusses the management of rheumatoid arthritis in the context of the current treatment landscape. This video is part of the course Fast Facts: IL-6 Receptor Inhibition in Rheumatoid Arthritis, which is free-to-access at this link.
Role of IL-6R inhibition in JIA-associated uveitis
Prof. Athimalaipet Ramanan elaborates on how interleukin-6 receptor inhibition therapy is prescribed and monitored in patients with JIA-associated uveitis. The video is part of the course Fast Facts: IL-6Ri in Juvenile Idiopathic Arthritis, which is free-to-access at this link.
Role of IL-6 in juvenile idiopathic arthritis
Dr. Marco Gattorno explains the the role of interleukin 6 receptor inhibition in juvenile idiopathic arthritis. It is part of the course Fast Facts: Interleukin-6 Receptor Inhibition in Juvenile Idiopathic Arthritis, which is free-to-access at this link.
Introduction to juvenile idiopathic arthritis
Prof. Fabrizio de Benedetti explains the differences between systemic juvenile idiopathic arthritis and polyarticular juvenile idiopathic arthritis, and how these conditions affect patients and their families. The video is part of the course Fast Facts: Interleukin-6 Receptor Inhibition in Juvenile Idiopathic Arthritis, which is free-to-access at this link.
Monitoring for giant cell arthritis
Prof. Bhaskar Dasgupta explains what optimal monitoring for patients with giant cell arteritis should look like. The video is part of the course Fast Facts: Interleukin-6 Receptor Inhibition in Giant Cell Arteritis, which is free-to-access at this link.
IL6 receptor inhibition in giant cell arthritis
Dr. Georgina Espígol-Frigolé and Dr. Christian Dejaco explain how tocilizumab and its biosimilars are currently used in the management of giant cell arthritis. The video is part of the course Fast Facts: Interleukin-6 Receptor Inhibition in Giant Cell Arteritis, which is free-to-access at this link.
Treatment of giant cell arthritis
Dr. Christian Dejaco explains when tocilizumab can be initiated in patients ‘at risk of glucocorticoid-related adverse events. The video is part of the course Fast Facts: Interleukin-6 Receptor Inhibition in Giant Cell Arteritis, which is free-to-access at this link.
Clinical presentation of giant cell arthritis
Prof. David Saadoun explains important considerations around the clinical presentation of giant cell arthritis. The video is part of the course Fast Facts: Interleukin-6 Receptor Inhibition in Giant Cell Arteritis, which is free-to-access at this link.
Interleukin-6 receptor inhibition: mechanism of action
This animation explains the mechanism of action of interleukin-6, and its role in treatment of different types of arthritis.
The video is part of the Fast Facts: Interleukin-6 Receptor courses:
Fast Facts: Interleukin-6 Receptor Inhibition in Giant Cell Arteritis
Fast Facts: Interleukin-6 Receptor Inhibition in Juvenile Idiopathic Arthritis
Fast Facts: Interleukin-6 Receptor Inhibition in Rheumatoid Arthritis
eLearning
Fast Facts: Interleukin-6 Receptor Inhibition in Rheumatoid Arthritis
Overview of the management of rheumatoid arthritis with interleukin-6 receptor inhibition therapy, with a specific focus on tocilizumab and its biosimilars.
Fast Facts: Interleukin-6 Receptor Inhibition in Giant Cell Arteritis
Overview of the management of giant cell arteritis with interleukin-6 receptor inhibition therapy, with a specific focus on tocilizumab and its biosimilars.
Fast Facts: Interleukin-6 Receptor Inhibition in Juvenile Idiopathic Arthritis
Overview of the management of juvenile idiopathic arthritis with interleukin-6 receptor inhibition therapy, with a specific focus on tocilizumab and its biosimilars.